Legend Biotech Corporation (LEGN) announced that the U.S. FDA cleared the IND application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. The clearance supports a planned U.S. Phase 1/2 study that will evaluate safety, tolerability, pharmacokinetics and preliminary efficacy.
LB2501 is designed as an off-the-shelf therapy that generates CAR-T cells inside the patient after a single infusion, and is being evaluated without lymphodepleting chemotherapy. The therapy is also being evaluated in an ongoing Phase 1 open-label study in China for relapsed or refractory B-cell malignancies.
Legend Biotech Corporation announced that CARVYKTI® generated approximately $710 million in net trade sales during the quarter ended September 30, 2026. The sales figure is based on information provided by Janssen, which Legend Biotech has not independently verified.
The amount of revenue or gross profit Legend Biotech will record in its consolidated statement of operations for the quarter is subject to management’s completion of the financial statements. The company’s independent registered public accountants have not audited, reviewed or performed procedures on the sales data and have provided no assurance about it.
Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders sold 27,370 ordinary shares on September 29, 2026, at a weighted average price of $9.4600 per share; individual sale prices ranged from $9.445 to $9.48. The sale was reported as a direct transaction, and no Rule 10b5-1 plan is reported. Sanders held 52,731 ordinary shares following the sale.
Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders reported a proposed sale of 13,685 American Depositary Shares, with an aggregate market value of $258,914.97 and an approximate sale date of September 29, 2026. Fidelity Brokerage Services LLC is listed as the broker, and the sale schedule attributes the shares to restricted-stock vesting.
Legend Biotech Corp director Peter Salovey received an award of 28,330 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027; the remainder vest in 12 equal quarterly installments beginning on March 20, 2028, subject to his continued service on each vesting date. His reported direct holding following the transaction was 55,096 ordinary shares.
Legend Biotech Corp (LEGN) director Tomas J. Heyman acquired 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings after the grant were 53,720 ordinary shares. The ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS representing two ordinary shares.
Legend Biotech Corp (LEGN) director Li Mao received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. The reported direct position following the award was 65,316 ordinary shares.
Legend Biotech Corp director Patrick John Casey received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to Casey's continued service on each vesting date. His reported direct holdings following the transaction were 69,590 ordinary shares.
Legend Biotech Corp director Darren Xiaohui Ji acquired 28,330 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to his continued service on each vesting date. His reported direct position following the transaction was 92,103 ordinary shares.
Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders received an award of 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share. One-third will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. Reported direct holdings following the award were 80,101 shares.